Australian researchers have identified a molecular vulnerability that could help explain why triple-negative breast cancer so readily spreads through the body—and may have revealed a way to repurpose an existing cancer drug against it. The study, led by scientists at Adelaide University and the Olivia Newton-John Cancer Research Institute, describes a regulatory system involving a small RNA molecule called miR-342 and a cancer-associated pathway known as E2F. In laboratory and animal models, the interaction between these two components helped determine whether disseminated breast cancer cells remained dormant or developed into metastatic tumours. The findings raise the possibility that molecular testing could identify a subset of patients with triple-negative breast cancer who might benefit from treatments not currently used routinely for this disease.
Triple-negative breast cancer, or TNBC, accounts for approximately 10–15% of breast cancer diagnoses in Australia and is defined by the absence of three major therapeutic targets: the oestrogen receptor, the progesterone receptor and the HER2 protein. Because these markers are missing, drugs designed to block hormone signalling or HER2-driven growth are generally ineffective. TNBC can respond to chemotherapy, immunotherapy and other emerging treatments, but it is biologically diverse and frequently returns after initial therapy. Once cancer cells escape from the primary tumour and establish themselves in organs such as the lungs, liver, brain or bones, treatment becomes substantially more difficult. Metastatic disease is responsible for most breast cancer deaths, making the mechanisms controlling spread a central focus of cancer research.
The new research found that patients whose tumours contained low levels of miR-342 and high activity in the E2F pathway were more likely to develop metastatic disease. MicroRNAs such as miR-342 are short strands of RNA that do not usually encode proteins. Instead, they regulate gene activity by binding to messenger RNA molecules and influencing whether specific proteins are produced. In this case, miR-342 appears to restrain a broad network of genes associated with cell-cycle progression, survival and metastatic growth. When miR-342 levels decline, that restraint is weakened. E2F, a family of transcription factors that activates genes needed for cell division, can then become excessively active, creating conditions in which cancer cells that have already travelled away from the original tumour can begin multiplying.
This mechanism may help resolve a longstanding puzzle in breast cancer biology. Cancer cells can enter the bloodstream or lymphatic system relatively early, yet they may remain clinically invisible for years before producing secondary tumours. The researchers’ findings suggest that low miR-342 may help convert these dormant disseminated cells into actively growing metastatic colonies. Rather than acting as a single switch controlling one gene, miR-342 appears to regulate an interconnected programme involving the E2F network. Such a programme could influence how cancer cells respond to signals from distant tissues, whether they remain quiescent and how efficiently they re-enter the cell cycle. The result is a biological state that may favour the emergence of metastases long after treatment of the primary tumour.
The team then tested whether restoring miR-342 could suppress this process. In pre-clinical models, increasing miR-342 markedly reduced the ability of breast cancer cells to spread and form tumours in other organs, including the lungs and bones. These experiments provided functional evidence that the molecule is not merely a passive marker associated with better outcomes. Its restoration altered the behaviour of the cancer cells themselves. The work also supports the idea that a tumour’s metastatic potential may be partly determined by regulatory RNA networks that sit above individual cancer genes, coordinating the activity of many pathways at once. However, the findings were generated in experimental systems and do not yet demonstrate that miR-342-based treatment is safe or effective in patients.
The researchers also investigated palbociclib, a drug that blocks cyclin-dependent kinases 4 and 6, or CDK4/6. These enzymes normally help push cells through a critical checkpoint in the cell cycle. By inhibiting CDK4/6, palbociclib prevents the activation of proteins required for progression from the first growth phase into DNA replication. The drug is approved for advanced hormone receptor-positive breast cancer, where abnormal cell-cycle signalling is a major feature of the disease. Because E2F activity is closely linked to this same cell-cycle machinery, the team asked whether CDK4/6 inhibition could counter the metastatic behaviour associated with low miR-342.
In models containing low levels of miR-342, palbociclib significantly reduced the growth of metastatic tumours. The timing of treatment appeared especially important: administering the drug after cancer cells had already disseminated was particularly effective at preventing microscopic deposits from developing into established secondary tumours. This result suggests that CDK4/6 inhibition may have value beyond shrinking a visible primary tumour. It could potentially suppress the outgrowth of residual cancer cells that have entered distant organs but have not yet formed detectable lesions. The researchers describe this as a treatment strategy for a biologically defined subgroup rather than a universal therapy for all triple-negative breast cancers. Measuring miR-342 and E2F activity could therefore become a way of selecting patients most likely to respond.
Associate Professor Philip Gregory of Adelaide University’s Centre for Cancer Biology and SA Pathology, a co-senior author of the study, said the work identified patients whose tumours appear to depend on a particular molecular pathway for metastatic progression. Professor Robin Anderson of the Olivia Newton-John Cancer Research Institute, also a co-senior author, emphasised that triple-negative breast cancer is highly heterogeneous, meaning that apparently similar tumours can rely on very different biological mechanisms. The miR-342-E2F network could provide one explanation for why some tumours spread aggressively and why others respond differently to treatment. The research also illustrates the potential advantage of targeting metastatic biology directly, rather than focusing exclusively on the primary tumour. Blocking the transition from dormant disseminated cells to expanding metastases could become an important component of future treatment.
The next stage will involve validating the findings in additional patient-derived models and determining how reliably miR-342 and E2F activity can be measured in clinical samples. Researchers will need to establish whether the molecular signature can be detected in routinely collected tumour tissue, whether it remains stable over time and whether it predicts response specifically to CDK4/6 inhibitors. Clinical trials will also be required to determine appropriate dosing, treatment timing and combinations with chemotherapy, immunotherapy or other targeted medicines. Palbociclib can produce side effects, including reduced blood-cell counts and increased susceptibility to infection, so its potential use in TNBC would require careful risk–benefit assessment. For now, the study offers a compelling pre-clinical rationale for repurposing an established drug while providing a molecular framework for identifying patients whose metastatic cancers may carry this targetable weakness.
The study, titled “Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network,” was published in EMBO Molecular Medicine. Its results do not yet change standard treatment for triple-negative breast cancer, but they point toward a more personalised approach in which metastatic risk and drug selection are guided by the regulatory state of each tumour. If future studies confirm that low miR-342 and elevated E2F activity identify patients who benefit from CDK4/6 inhibition, a therapy already used in another form of breast cancer could be extended to a carefully selected TNBC population. The broader implication is that dormant cancer cells may not be therapeutically untouchable: by identifying the molecular signals that awaken them, researchers may be able to intervene before small, hidden deposits become life-threatening disease.
Subject of Research: Animals
Article Title: Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network
News Publication Date: 21-Aug-2026
Web References: https://link.springer.com/article/10.1038/s44321-026-00496-4; https://www.onjcri.org.au/; https://researchers.adelaide.edu.au/profile/philip.gregory
References: EMBO Molecular Medicine, DOI: 10.1038/s44321-026-00496-4
Image Credits: Adelaide University
Keywords: Triple-negative breast cancer, breast cancer metastasis, miR-342, E2F pathway, CDK4/6 inhibitors, palbociclib, cancer dormancy, precision oncology, metastatic cancer, molecular biology
